The Food and Drug Administration has issued a long-awaited approval of Novavax’s COVID-19 vaccine but with unusual ...

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

The U.S. Food and Drug Administration on Friday approved Novavax's COVID-19 vaccine, but placed additional conditions on ...

Covid shots are facing greater scrutiny from top federal health officials like RFK Jr. and the FDA's Marty Makary.

The vaccine will only be available to those at high risk from Covid—excluding those who may need it to protect a relative or ...

The US Food and Drug Administration (FDA) has approved Novavax's Covid-19 vaccine, Nuvaxovid, but only for limited use in ...

Novavax (NVAX) stock in focus as the U.S. FDA approves its COVID-19 vaccine Nuvaxovid for high-risk groups in the U.S. Read ...

Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

Novavax is undervalued, presenting an attractive risk-reward profile for long-term investors. Click here to find out why NVAX ...

Novavax (NasdaqGS:NVAX) recently reported a significant financial turnaround for Q1 2025, demonstrating substantial revenue growth and net income improvements. The amending of its collaboration ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...